for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Genfit SA

GNFT.PA

Latest Trade

13.30EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

11.71

 - 

24.06

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
13.30
Open
--
Volume
--
3M AVG Volume
6.05
Today's High
--
Today's Low
--
52 Week High
24.06
52 Week Low
11.71
Shares Out (MIL)
38.83
Market Cap (MIL)
516.46
Forward P/E
-5.77
Dividend (Yield %)
--

Next Event

Genfit SA Annual Shareholders Meeting

Latest Developments

More

Genfit: H1 Net Loss Widens To Eur 51.1 Mln

Genfit Appoints Pascal Prigent As New CEO

Genfit And Terns Pharmaceuticals Announce $228 Million Strategic Partnership To Develop & Commercialize Elafibranor In Greater China

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Genfit SA

Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.

Industry

Biotechnology & Drugs

Contact Info

Parc Eurasante 885 avenue Eugene Avinee

+33.3.20164000

http://www.genfit.com

Executive Leadership

Jean-Francois Mouney

Chairman of the Board

Pascal Prigent

Chief Executive Officer

Xavier Guille Des Buttes

Independent Vice Chairman of the Board

Bart Staels

President of the Scientific Advisory Board, Member of the Management Board

Florence Sejourne

Director, Representative of Biotech Avenir

Key Stats

1.83 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (EUR)

2016

-1.250

2017

-1.880

2018

-2.550

2019(E)

-2.304
Price To Earnings (TTM)
--
Price To Sales (TTM)
66.82
Price To Book (MRQ)
5.38
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
186.16
LT Debt To Equity (MRQ)
181.62
Return on Investment (TTM)
-37.81
Return on Equity (TTM)
-32.74

Latest News

Latest News

BRIEF-Genfit Presents Additional Data from Positive Phase 2 Clinical Trial Of Elafibranor

* SAID ON SATURDAY FURTHER ANALYSIS SHOWS SIGNIFICANT IMPROVEMENTS IN PBC CHOLESTATIC MARKERS AND REDUCTION ON IMMUNO/INFLAMMATION MARKERS

BRIEF-Genfit Raises Circa $155.4 Million Gross In Nasdaq Offering

* ANNOUNCED ON THURSDAY EXERCISE IN FULL OF THE OPTION GRANTED TO THE UNDERWRITERS OF ITS GLOBAL OFFERING AND NASDAQ GLOBAL SELECT MARKET LISTING TO PURCHASE UP TO 997,500 ADDITIONAL ADSS

BRIEF-Genfit's Q1 revenues edge up compared to a year ago

* Revenues for the first three months of 2018 amounted to €37 thousand compared to €26 thousand for the same period in 2017

BRIEF-Genfit Announces Positive Outcome From The Safety Review By The DSMB

* REG-GENFIT : POSITIVE OUTCOME FROM THE 24-MONTH PRE-PLANNED SAFETY REVIEW BY THE DSMB, IN RESOLVE-IT PHASE 3 CLINICAL TRIAL WITH ELAFIBRANOR

BRIEF-Genfit announces milestone for RESOLVE-IT Phase 3 Trial

* Major Milestone for the RESOLVE-IT Phase 3 Trial on the Recruitment of the Interim Analysis Cohort

BRIEF-Genfit FY Net Loss Widens To 58.6 Million Euros

* 2017: A YEAR OF VERY SIGNIFICANT REINFORCEMENT OF THE CASH POSITION (€274M AT 12.31.2017), WITH ALL PROGRAMS IN THE COMPANY'S PIPELINE MOVING FORWARD

BRIEF-Genfit: Official Launch Of NASH Pediatric Program In US

* REG-GENFIT: OFFICIAL LAUNCH OF THE NASH PEDIATRIC PROGRAM, FOLLOWING PIP AND PSP AGREEMENT BY EMA AND FDA

BRIEF-Genfit announces positive outcome of DSMB safety review

* REG-GENFIT: POSITIVE OUTCOME FROM THE 18-MONTH PRE-PLANNED SAFETY REVIEW BY THE DSMB, IN RESOLVE-IT PHASE 3 CLINICAL TRIAL WITH ELAFIBRANOR

BRIEF-Genfit completes offering of convertible bonds due 2022 for 180 million euros

* REG-GENFIT COMPLETES A €180 MILLION OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANES") DUE 2022

BRIEF-Genfit completes convertible bonds offering for amount of 180 million euros

* REG-GENFIT ANNOUNCES THE SUCCESS OF ITS OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANES") DUE 2022 FOR AN AMOUNT OF €180 MILLION

BRIEF-Genfit reports‍ nine months revenues at 91 thousand euros

* CASH AND CASH EQUIVALENTS OF EUR 113.8 MILLION AT SEPTEMBER 30, 2017

BRIEF-Genfit launches an offering of conbertible bonds for around 150 million euros

* GENFIT LAUNCHES AN OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANES") DUE 2022 FOR AN AMOUNT OF APPROXIMATELY €150 MILLION

BRIEF-Genfit's combination of two pharmacopoeia​ drugs show anti-fibrotic potential

* NEW RESULTS INDICATING A SUBSTANTIAL ANTI-FIBROTIC POTENTIAL OF A PROPRIETARY COMBINATION OF TWO DRUGS FROM PHARMACOPOEIA

BRIEF-Genfit H1 operating loss widens to 22.4 million euros

* REG-GENFIT: 2017 HALF-YEAR RESULTS: CASH POSITION AT END OF PERIOD AT €126M AND SIGNIFICANT ADVANCES IN THE COMPANY'S PIPELINE

BRIEF-Genfit alerts public to potential risk of confusion between elafibranor and lanifibranor

* REG-GENFIT: RISK OF CONFUSION BETWEEN PPAR ALPHA/DELTA PHASE 3 DRUG CANDIDATE ELAFIBRANOR AND PPAR A/D/GAMMA PHASE 2 COMPOUND LANIFIBRANOR

BRIEF-Genfit says hits milestone towards development of non-invasive IVD test for NASH

* REG-GENFIT REACHES A CRITICAL MILESTONE TOWARDS THE DEVELOPMENT OF A NON-INVASIVE IN VITRO DIAGNOSTIC (IVD) TEST FOR NASH

BRIEF-Genfit announces positive outcome from safety review by the DSMB

* POSITIVE OUTCOME FROM THE 1-YEAR PRE-PLANNED SAFETY REVIEW BY THE DSMB, IN RESOLVE-IT PHASE 3 CLINICAL TRIAL WITH ELAFIBRANOR Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Genfit enrolls first patient in phase 2 trial on rare liver disease

* First patient enrolled in a phase 2 trial recruiting adults with primary biliary cholangitis (PBC), a rare liver disease Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

BRIEF-Genfit cash and cash equivalents at March 31 rises to 137.0 million euros

* Q1 revenue 26,000 euros ($28,176.20) versus 88,000 euros year ago

BRIEF-Genfit initiates paediatric NAFLD/NASH program in Europe

* Genfit initiates paediatric NAFLD/NASH program in Europe further to the approval of elafibranor's paediatric investigation plan by the EMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up